New Mexico § 26-2D-3 Definitions

New Mexico Statutes

§ 26-2D-3 — Definitions

New Mexico § 26-2D-3

Ch. 26Drugs and Cosmetics

Art. 2DMedical Psilocybin

This text of New Mexico § 26-2D-3 (Definitions) is published on Counsel Stack Legal Research, covering New Mexico primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

N.M. Stat. Ann. § 26-2D-3 (2026).

Text

As used in the Medical Psilocybin Act: A. "board" means the medical psilocybin advisory board; B. "clinician" means an approved health care provider licensed in New Mexico who holds a permit from the department to provide medical services to qualified patients; C. "department" means the department of health; D. "medical services" means services provided to a patient in an approved setting before, during and after the ingestion of psilocybin and includes a preparation session, an administration session and an integration session; E. "producer" means a person who has a permit from the department to grow and harvest or prepare psilocybin from psilocybin-producing mushrooms, including to compound, convert, process or manufacture psilocybin products directly or indirectly from psilocybin mushro

Free access — add to your briefcase to read the full text and ask questions with AI

As used in the Medical Psilocybin Act: A. "board" means the medical psilocybin advisory board; B. "clinician" means an approved health care provider licensed in New Mexico who holds a permit from the department to provide medical services to qualified patients; C. "department" means the department of health; D. "medical services" means services provided to a patient in an approved setting before, during and after the ingestion of psilocybin and includes a preparation session, an administration session and an integration session; E. "producer" means a person who has a permit from the department to grow and harvest or prepare psilocybin from psilocybin-producing mushrooms, including to compound, convert, process or manufacture psilocybin products directly or indirectly from psilocybin mushrooms and to package or repackage or label or relabel the products; F. "program" means the medical use of psilocybin program; G. "psilocybin" means the naturally occurring psychedelic compound 4- phosphoryloxy-N,N-dimethyltryptamine, also known as 4-PO-DMT, and its pharmacologically active metabolite psilocin, 4-hydroxy-N,N-dimethyltryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin; H. "qualified patient" means a patient whose clinician has judged the patient to be a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition; I. "qualifying condition" includes: (1) major treatment-resistant depression; (2) posttraumatic stress disorder; (3) substance use disorders; (4) end-of-life care; and (5) other conditions approved by the department; and J. "secretary" means the secretary of health.